Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Gabriel N HortobagyiSalomon M StemmerHoward A BurrisYoon-Sim YapGabe S SonkeLowell HartMario CamponeKatarina PetrakovaEric P WinerWolfgang JanniPierfranco ConteDavid A CameronFabrice AndréCarlos L ArteagaJuan P ZarateArunava ChakravarttyTetiana TaranFabienne Le GacPaolo SerraJoyce O'Shaughnessy

Published in: The New England journal of medicine (2022)

First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo. (Funded by Novartis; MONALEESA-2 ClinicalTrials.gov number, NCT01958021.).

Keyphrases

polycystic ovary syndrome
free survival
early breast cancer
type diabetes
double blind
adipose tissue
metabolic syndrome
young adults
bone marrow
metastatic breast cancer